BioSpace News Archive

Rakuten Medical, Inc. announced that data from a phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma was accepted for publication in Head and Neck and published online on October 9th, 2021.

Biohaven Pharma Holding Company Ltd. (NYSE: BHVN), announced the enrollment of the first patient in a Phase 1a/1b trial in Multiple Myeloma using the ARM, BHV-1100

Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced that Histogen’s financial results for the third quarter will be released after the close of market on Wednesday, November 10, 2021.

Monopar Therapeutics Inc. today announced that the first patient has been dosed in its open-label dose-escalation Phase 1b clinical trial evaluating camsirubicin for the treatment of advanced soft tissue sarcoma (ASTS).

Medicenna Announces FDA Clearance of IND to Expand the Phase 1/2 ABILITY Study of MDNA11 to the United States

Solaris Pharma Corporation (“Solaris”) announced today that the U.S. Food and Drug Administration (FDA) has approved its abbreviated new drug application (ANDA) for a generic version of Metrogel-Vaginal® (metronidazole vaginal gel 0.75%) by Bausch Health. This product will be launched immediately.

ANGUS Chemical Company today announced the appointment of Jonathan Arnold to the Company’s Board of Directors.

New Members Add Deep Expertise in Translational and Clinical Drug Development, Corporate Strategy and Finance, Regulatory Affairs, and Investment

INOVIO (NASDAQ: INO) announced today that third quarter 2021 financial results will be released after the market close on November 9, 2021

Acurx Pharmaceuticals, Inc. announced today that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021 , at 8:30 am